Logo

Achaogen's Zemdri (plazomicin) Receives FDA Approval for Complicated Urinary Tract Infection (cUTI)

Share this

Achaogen's Zemdri (plazomicin) Receives FDA Approval for Complicated Urinary Tract Infection (cUTI)

Shots:

  • The approval is based on P-III EPIC (Evaluating Plazomicin in cUTI) study results assessing Zemdri (plazomicin- IV) vs Meropenem in 388 patients with cUTI including pyelonephritis aged ≥18 yrs.
  • P-IIIEPIC study results: composite cure rate (CCR) @5 day (88.0% vs 91.4%); CCR at test-of-cure (TOC) (81.7% vs 70.1%)
  • Zemdri (plazomicin- qd) is an aminoglycoside active against carbapenem-resistant (CRE) & extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae used for targetting bacterias including E.coli- Klebsiella pneumoniae and Enterobacter cloacae 

Ref: Achaogen | Image: Achaogen

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions